Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors.
about
Outcomes of treatment for hepatitis C virus infection by primary care providersConceptual framework for outcomes research studies of hepatitis C: an analytical reviewTangible resources for preparing patients for antiviral therapy for chronic hepatitis CCorrelates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designEligibility of persons who inject drugs for treatment of hepatitis C virus infection.Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factorsThe treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection.Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver diseaseRate, delay and predictors of hepatitis C treatment in British ColumbiaChronic hepatitis C and antiviral treatment regimens: where can psychology contribute?Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health centerPatients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection.Access to care for vulnerable veterans with hepatitis C: a hybrid conceptual framework and a case study to guide translationThe new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study.Antiviral therapy for hepatitis C: why are so few patients being treated?Quality of care for gastrointestinal conditions: a primer for gastroenterologists.Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers.Relative effects of heavy alcohol use and hepatitis C in decompensated chronic liver disease in a hospital inpatient population.Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs.Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration.Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.The performance of process measures in hepatitis C.Public health impact of antiviral therapy for hepatitis C in the United States.Provider and Site-Level Determinants of Testosterone Prescribing in the Veterans Healthcare System.Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response.Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.
P2860
Q24601722-0CB7AA7B-179C-4A01-A46D-2758386E7C89Q26745582-64E58D71-E235-4C8B-98A9-8A7470090701Q26858962-EC79BED2-FC68-4D56-AAF6-BBCB8707ABF2Q28546457-AF2E6BA9-9CC1-489B-B8FE-3F44CC1BA136Q30374314-ACDFCC40-AD75-49AF-9F5E-2E5080DAC014Q30429470-DB5D6907-0108-4577-9439-DC8841E74745Q33716634-58A3747C-B83D-40F9-A320-A4399A2DEEC1Q33837518-7A9C8CB1-BC60-41D1-BD0B-71B61A184716Q34191840-947D4DF4-6A6F-4448-A0B0-1698B9167D81Q34643724-774AFAEA-26E3-45A2-A4C1-ECDE5680792DQ34777639-01456326-8E39-4907-ABDC-F1E5A5C891D8Q35997794-2EC69BBF-41CB-4D2B-AA3D-3445B7910780Q36082161-5ABD8E8E-F127-48CC-8907-D3F2354BAB84Q36418455-A0ECF433-0ECB-4BEF-97BD-7670A41288C2Q36421892-BAC7592B-508D-48F0-BBCB-A12A7114C68AQ36771385-B788A01D-D3BA-4771-970E-529771DE8D8CQ36789904-3423A1DA-B485-4E9A-A48D-88179753E834Q37021514-9870F773-EDAD-4043-A874-E6B24B09E9A4Q37030555-B350A152-7070-4844-AE6E-86A61E7A3C9FQ37455611-1EA2CEE0-C190-4FC7-A5A2-0F87D027EADBQ37701782-728C481C-AA15-4985-83C8-C3C55BCCBF9CQ37749115-D6BC271A-F285-44FC-A9EF-D77E24493474Q37897917-136790DF-B99C-411E-868C-2752E8C6C30BQ38064495-19834045-EFD3-4485-B9CC-4E12233C56AAQ38260704-FE9DDD08-BA69-40ED-B7C7-32D5D49EB740Q38323723-7805194C-C058-4298-9202-1A9A032A9F8CQ38407675-BD95326A-9247-4FA0-9E4F-553A52C90051Q38921949-A3191949-8C63-44B5-B3AD-9D47EB11E7F2Q38933599-67ABDD60-4083-47EE-BC90-C9F14F75918FQ39269740-580E9B60-0B94-467A-AE93-C440E8A0E44DQ39589157-816DD1FE-82FF-46E8-BE2A-F4B874DEA348Q39939298-B50A060E-F7EA-4915-AF88-715FE09DC931Q40040723-36553909-8989-4C5F-9DAF-1AC8473985DFQ40064478-CD0EBB3B-51CD-4F74-B1DD-7313CBF80AF5Q40078740-B4CC307C-811F-49D2-8546-77C1BB29BAF9Q40098372-CD411C5E-32D0-4383-8773-505187594A47Q40111638-C3EE3899-A114-4D86-93D3-C41326667F07Q41047662-65FB51BC-1E4F-4D12-AB47-140EC63F8284Q41089743-73304119-909E-492A-817C-3EB20ACA26D3Q41210837-40DA76ED-5802-48C1-9284-7CA42B81BAB3
P2860
Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Predictors of treatment in pat ...... ent versus nonpatient factors.
@ast
Predictors of treatment in pat ...... ent versus nonpatient factors.
@en
Predictors of treatment in pat ...... ent versus nonpatient factors.
@nl
type
label
Predictors of treatment in pat ...... ent versus nonpatient factors.
@ast
Predictors of treatment in pat ...... ent versus nonpatient factors.
@en
Predictors of treatment in pat ...... ent versus nonpatient factors.
@nl
prefLabel
Predictors of treatment in pat ...... ent versus nonpatient factors.
@ast
Predictors of treatment in pat ...... ent versus nonpatient factors.
@en
Predictors of treatment in pat ...... ent versus nonpatient factors.
@nl
P2093
P2860
P356
P1433
P1476
Predictors of treatment in pat ...... ent versus nonpatient factors.
@en
P2093
Allen Gifford
Brennan M R Spiegel
Fasiha Kanwal
Mathew Goetz
Seth Eisen
Steven M Asch
Tuyen Hoang
P2860
P304
P356
10.1002/HEP.21927
P407
P577
2007-12-01T00:00:00Z